These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10891461)

  • 1. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.
    Masdehors P; Merle-Béral H; Maloum K; Omura S; Magdelénat H; Delic J
    Blood; 2000 Jul; 96(1):269-74. PubMed ID: 10891461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.
    Masdehors P; Merle-Béral H; Magdelénat H; Delic J
    Leuk Lymphoma; 2000 Aug; 38(5-6):499-504. PubMed ID: 10953970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.
    Delic J; Masdehors P; Omura S; Cosset JM; Dumont J; Binet JL; Magdelénat H
    Br J Cancer; 1998 Apr; 77(7):1103-7. PubMed ID: 9569046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal DNA and p53 stability, ubiquitin system and apoptosis in B-CLL lymphocytes.
    Blaise R; Masdehors P; Laugé A; Stoppa-Lyonnet D; Alapetite C; Merle-Béral H; Binet JL; Omura S; Magdelénat H; Sabatier L; Delic J
    Leuk Lymphoma; 2001; 42(6):1173-80. PubMed ID: 11911398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
    Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
    Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways.
    Bogner C; Schneller F; Hipp S; Ringshausen I; Peschel C; Decker T
    Exp Hematol; 2003 Mar; 31(3):218-25. PubMed ID: 12644019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells.
    Zhang XM; Lin H; Chen C; Chen BD
    Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):127-33. PubMed ID: 10229667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin.
    Masdehors P; Omura S; Merle-Béral H; Mentz F; Cosset JM; Dumont J; Magdelénat H; Delic J
    Br J Haematol; 1999 Jun; 105(3):752-7. PubMed ID: 10354141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.
    Dewson G; Snowden RT; Almond JB; Dyer MJ; Cohen GM
    Oncogene; 2003 May; 22(17):2643-54. PubMed ID: 12730678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors.
    Kim OH; Lim JH; Woo KJ; Kim YH; Jin IN; Han ST; Park JW; Kwon TK
    Int J Oncol; 2004 Apr; 24(4):935-41. PubMed ID: 15010833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex.
    Almond JB; Snowden RT; Hunter A; Dinsdale D; Cain K; Cohen GM
    Leukemia; 2001 Sep; 15(9):1388-97. PubMed ID: 11516099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.
    Wagenknecht B; Hermisson M; Groscurth P; Liston P; Krammer PH; Weller M
    J Neurochem; 2000 Dec; 75(6):2288-97. PubMed ID: 11080180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells.
    Wagenknecht B; Hermisson M; Eitel K; Weller M
    Cell Physiol Biochem; 1999; 9(3):117-25. PubMed ID: 10494025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of proteasome function induced apoptosis in gastric cancer.
    Fan XM; Wong BC; Wang WP; Zhou XM; Cho CH; Yuen ST; Leung SY; Lin MC; Kung HF; Lam SK
    Int J Cancer; 2001 Aug; 93(4):481-8. PubMed ID: 11477551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis.
    Robertson JD; Datta K; Biswal SS; Kehrer JP
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):477-85. PubMed ID: 10567231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway.
    Lang-Rollin I; Vekrellis K; Wang Q; Rideout HJ; Stefanis L
    J Neurochem; 2004 Sep; 90(6):1511-20. PubMed ID: 15341534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo ubiquitination and proteasome-mediated degradation of p53(1).
    Maki CG; Huibregtse JM; Howley PM
    Cancer Res; 1996 Jun; 56(11):2649-54. PubMed ID: 8653711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells.
    Kitagawa H; Tani E; Ikemoto H; Ozaki I; Nakano A; Omura S
    FEBS Lett; 1999 Jan; 443(2):181-6. PubMed ID: 9989601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway.
    Nakajima T; Morita K; Tsunoda H; Imajoh-Ohmi S; Tanaka H; Yasuda H; Oda K
    J Biol Chem; 1998 Aug; 273(32):20036-45. PubMed ID: 9685342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.